WA-KYMETA
18.3.2024 13:01:27 CET | Business Wire | Press release
World-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com), announced today at SATELLITE 2024 that the Osprey u8 HGL, a hybrid geostationary/low Earth orbit (GEO/LEO/LTE) terminal purpose-built for military users, is shipping out of their facility in Woodinville, Washington. This marks the first commercially available multi-orbit terminal and the first multi-orbit terminal on Eutelsat OneWeb’s LEO network. Kymeta announced the official launch in October last year and is fulfilling a backlog of orders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318848741/en/
Kymeta - The Future of Military SATCOM is now. On the move GEO-LEO-LTE from one single terminal - Osprey u8 HGL (Graphic: Business Wire)
In February, the Kymeta team demonstrated in the field the capabilities of the new Osprey u8 HGL delivering resilient, auto-PACE ready communications for the armed forces to meet the demands of challenging and rugged military environments. The multi-orbit, multi-network capabilities of the Osprey u8 HGL terminal will offer even greater availability, while being durable, low power consuming, having low visibility, and easy to use.
The Osprey u8 HGL includes a field swappable modem cartridge and a OneWeb modem to enable connectivity with the Eutelsat OneWeb LEO network. At launch an iDirect 950mp cartridge is available enabling TRANSEC services over GEO. Other cartridge configurations will be available soon enabling end users to customize their terminal configuration based on their mission needs.
Initial feedback was overwhelmingly positive, with one military member stating: “This is everything we’ve been looking for in a terminal, form function and features. The LEO to GEO switching far exceeded our expectations. It’s amazing that Kymeta is already delivering on the community’s urgent need for multi-orbit SATCOM.”
Others in attendance at Army field demonstrations commented, “I cannot wait to get started with these!” and “Wow! It tracks satellites over some very difficult terrain.”
“The Kymeta Osprey HGL has a unique capability to address government requirements in support of government PACE plans,” said Ian Canning, Chief Operating Officer, OneWeb Technologies. “The Osprey supports multi-network/orbit requirements through the concurrent LTE/satellite configuration with the added benefit of now being able to add OneWeb LEO capabilities.”
Jon Osler, Senior Vice President Global Sales and Services of Kymeta, commented: “In the contemporary military landscape, mobile connectivity has become indispensable for achieving success. Unlike any other sector, the military relies heavily on dependable, adaptable, and resilient on-the-go communication systems to fulfill its operational and training needs. We take pride in our longstanding partnership with the military, delivering cutting-edge solutions that meet and exceed expectations.”
This milestone further establishes Kymeta as the leader in the multi-X revolution. Attendees of SATELLITE 2024 in Washington, DC, March 18– 20 are encouraged to visit Kymeta’s meeting room 156 to see the Osprey u8 HGL in person and to speak with a member of the Kymeta team.
About Kymeta
Kymeta is the industry leader in flat panel satellite antennas, providing purpose-built solutions across a variety of enterprise and military applications and unlocking the commercial value of space to address the vast, unmet demand for ubiquitous broadband and truly mobile connectivity for customers around the world. Its innovative metasurface technology, coupled with a software-first approach, delivers the first commercially available, metamaterial-based and electronically steered flat panel satellite antenna. Kymeta’s low-cost, low power and high throughput solutions make it easy to connect on the move or while stationary – for any vehicle, vessel, aircraft, or fixed platform – enabling industries on earth to transform their operations by harnessing capacity in space.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318848741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom